Mohammed Almannai1, Ronit Marom1, Kristian Divin2, Fernando Scaglia1, V Reid Sutton1, William J Craigen1, Brendan Lee1, Lindsay C Burrage3, Brett H Graham4. 1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Human Genetics, Texas Children's Hospital, Houston, TX, USA. 2. Department of Molecular and Human Genetics, Texas Children's Hospital, Houston, TX, USA. 3. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Human Genetics, Texas Children's Hospital, Houston, TX, USA. Electronic address: Burrage@bcm.edu. 4. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Human Genetics, Texas Children's Hospital, Houston, TX, USA. Electronic address: bgraham@bcm.edu.
Abstract
INTRODUCTION: Cobalamin C disease is a multisystemic disease with variable manifestations and age of onset. Genotype-phenotype correlations are well-recognized in this disorder. Here, we present a large cohort of individuals with cobalamin C disease, several of whom are heterozygous for the c.482G>A pathogenic variant (p.Arg161Gln). We compared clinical characteristics of individuals with this pathogenic variant to those who do not have this variant. To our knowledge, this study represents the largest single cohort of individuals with the c.482G>A (p.Arg161Gln) pathogenic variant. METHODS: A retrospective chart review of 27 individuals from 21 families with cobalamin C disease who are followed at our facility was conducted. RESULTS: 13 individuals (48%) are compound heterozygous with the c.482G>A (p.Arg161Gln) on one allele and a second pathogenic variant on the other allele. Individuals with the c.482G>A (p.Arg161Gln) pathogenic variant had later onset of symptoms and easier metabolic control. Moreover, they had milder biochemical abnormalities at presentation which likely contributed to the observation that 4 individuals (31%) in this group were missed by newborn screening. CONCLUSION: The c.482G>A (p.Arg161Gln) pathogenic variant is associated with milder disease. These individuals may not receive a timely diagnosis as they may not be identified on newborn screening or because of unrecognized, late onset symptoms. Despite the milder presentation, significant complications can occur, especially if treatment is delayed.
INTRODUCTION:Cobalamin C disease is a multisystemic disease with variable manifestations and age of onset. Genotype-phenotype correlations are well-recognized in this disorder. Here, we present a large cohort of individuals with cobalamin C disease, several of whom are heterozygous for the c.482G>A pathogenic variant (p.Arg161Gln). We compared clinical characteristics of individuals with this pathogenic variant to those who do not have this variant. To our knowledge, this study represents the largest single cohort of individuals with the c.482G>A (p.Arg161Gln) pathogenic variant. METHODS: A retrospective chart review of 27 individuals from 21 families with cobalamin C disease who are followed at our facility was conducted. RESULTS: 13 individuals (48%) are compound heterozygous with the c.482G>A (p.Arg161Gln) on one allele and a second pathogenic variant on the other allele. Individuals with the c.482G>A (p.Arg161Gln) pathogenic variant had later onset of symptoms and easier metabolic control. Moreover, they had milder biochemical abnormalities at presentation which likely contributed to the observation that 4 individuals (31%) in this group were missed by newborn screening. CONCLUSION: The c.482G>A (p.Arg161Gln) pathogenic variant is associated with milder disease. These individuals may not receive a timely diagnosis as they may not be identified on newborn screening or because of unrecognized, late onset symptoms. Despite the milder presentation, significant complications can occur, especially if treatment is delayed.
Authors: Jordan P Lerner-Ellis; Jamie C Tirone; Peter D Pawelek; Carole Doré; Janet L Atkinson; David Watkins; Chantal F Morel; T Mary Fujiwara; Emily Moras; Angela R Hosack; Gail V Dunbar; Hana Antonicka; Vince Forgetta; C Melissa Dobson; Daniel Leclerc; Roy A Gravel; Eric A Shoubridge; James W Coulton; Pierre Lepage; Johanna M Rommens; Kenneth Morgan; David S Rosenblatt Journal: Nat Genet Date: 2005-11-27 Impact factor: 38.330
Authors: Martina Huemer; Burkhard Simma; Brian Fowler; Terttu Suormala; Olaf A Bodamer; Jörn Oliver Sass Journal: J Pediatr Date: 2005-10 Impact factor: 4.406
Authors: Sandra G Heil; Marije Hogeveen; Leo A J Kluijtmans; P J van Dijken; Gerard B van de Berg; Henk J Blom; Eva Morava Journal: J Inherit Metab Dis Date: 2007-09-04 Impact factor: 4.982
Authors: Anne Chun-Hui Tsai; Chantal F Morel; Gunter Scharer; Michael Yang; Jordan P Lerner-Ellis; David S Rosenblatt; Janet A Thomas Journal: Am J Med Genet A Date: 2007-10-15 Impact factor: 2.802
Authors: Jordan P Lerner-Ellis; Natascia Anastasio; Junhui Liu; David Coelho; Terttu Suormala; Martin Stucki; Amanda D Loewy; Scott Gurd; Elin Grundberg; Chantal F Morel; David Watkins; Matthias R Baumgartner; Tomi Pastinen; David S Rosenblatt; Brian Fowler Journal: Hum Mutat Date: 2009-07 Impact factor: 4.878
Authors: Johan L K Van Hove; Rita Van Damme-Lombaerts; Stephanie Grünewald; Heidi Peters; Boudewijn Van Damme; Jean-Pierre Fryns; Jozef Arnout; Ron Wevers; E Regula Baumgartner; Brian Fowler Journal: Am J Med Genet Date: 2002-08-01
Authors: Gang Peng; Christina A de Fontnouvelle; Gregory M Enns; Tina M Cowan; Hongyu Zhao; Curt Scharfe Journal: Mol Genet Metab Date: 2018-11-10 Impact factor: 4.797
Authors: Julia C van Campen; Elizabeth S A Sollars; Rebecca C Thomas; Clare M Bartlett; Antonio Milano; Matthew D Parker; Jennifer Dawe; Peter R Winship; Gerrard Peck; Darren Grafham; Richard J Kirk; James R Bonham; Anne C Goodeve; Ann Dalton Journal: Int J Neonatal Screen Date: 2019-11-05